MYOMO, INC.
Customers
3
0 disclosed, 1 federal agency
Suppliers
0
None disclosed
Largest customer
—
No % disclosed
Named-customer revenue
—
No estimate available
Federal obligations
$1.3M
FY2024 · USAspending.gov
Latest period
Sep 30, 2024
10-Q filed 2024-11-06
Customers 2
Companies MYO discloses as major customers, as a share of MYO revenue. 0 active, 2 lapsed.
| Company | % of MYO revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| Patients With Medicare Part B Coverage Non-SEC Patients With Medicare Part B Coverage |
55% | $5.1M | 3M 2024-09-30 | +8.0pp | Lapsed Last seen 2024-09-30 |
10-Q 2024-11-06 |
For the three and nine months ended September 30, 2024, patients with Medicare Part B coverage represented 55% and 44% of product revenues, respectively. For the three and six months ended June 30, 2024, patients with Medicare Part B coverage represented 47% and 35% of product revenues, respectively. | ||||||
| Patients With Medicare Advantage Insurance Plans Non-SEC Patients With Medicare Advantage Insurance Plans |
24% | $2.2M | 3M 2024-09-30 | −2.0pp | Lapsed Last seen 2024-09-30 |
10-Q 2024-11-06 |
For the three and nine months ended September 30, 2024, approximately 24% and 27% of the Company's product revenues, respectively, were derived from patients with Medicare Advantage insurance plans. For the three and six months ended June 30, 2024, approximately 26% and 30% of the Company's product revenues, respectively, were derived from patients with Medicare Advantage insurance plans. For the year ended December 31, 2023, approximately 57% of our product revenues were derived from patients with Medicare Advantage insurance plans. For the three and nine months ended September 30, 2023, approximately 59% and 59% of the Company's product revenues, respectively, were derived from patients with Medicare Advantage insurance plans. For the three and six months ended June 30, 2023, approximately 63% and 59% of the Company's product revenues were derived from patients with Medicare advantage insurance plans, respectively. For the three months ended March 31, 2024 and 2023, approximately 38% and 53% of the Company's product revenues, respectively, were derived from patients with Medicare Advantage insurance plans. For the year ended December 31, 2023 and 2022, approximately 57% and 60% of the Companys product revenues were derived from patients with Medicare Advantage insurance plans, respectively. For the three and nine months ended September 30, 2022, approximately 62% and 62% of the Company’s product revenues were derived from patients with Medicare Advantage insurance plans, respectively. For the three and six months ended June 30, 2022, approximately 71% and 63% of the Company’s product revenues were derived from patients with Medicare Advantage insurance plans, respectively. For the year ended December 31, 2022 and 2021, approximately 60% and 59% of the Company's product revenues were derived from patients with Medicare Advantage insurance plans, respectively. For the three and nine months ended September 30, 2021, approximately 71% and 62% of the Company’s product revenues were derived from patients with Medicare Advantage insurance plans, respectively. For the three and six months ended June 30, 2021, approximately 52% and 54% of the Company’s product revenues were derived from patients with Medicare Advantage insurance plans, respectively. For the three months ended March 31, 2022 and 2021, approximately 52% and 56% of the Company’s product revenues were derived from patients with Medicare Advantage insurance plans, respectively. For the year ended December 31, 2021 and 2020, approximately 59% and 50% of our revenues were derived from patients with Medicare Advantage insurance plans, respectively. | ||||||
Federal contracts 1
Agencies that awarded contracts to this company, from USAspending.gov. Dollars are obligated amounts as reported, not estimates; $1.3M in the latest fiscal year shown per agency.
| Agency | Obligated | Fiscal year | Awards | Trend | Largest award |
|---|---|---|---|---|---|
| Department of Veterans Affairs
Department of Veterans Affairs |
$1.3M | FY 2024 | 53 | 36C25724K0345 | |
EXPRESS REPORT: L8702 - MYOPRO 2 WITH MOTION GRASP LEFT | |||||
Named as competitors
Companies this filer names as competitors.
Alerts are coming
Get an email when MYO's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.